Associations of neuromelanin in the substantia nigra with antipsychotic response in schizophrenia
Authors:
- 7 November 2025
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-9
Abstract
Approximately 30% of patients with schizophrenia do not respond to antipsychotics. While schizophrenia has been primarily explained by the dopamine dysfunction hypothesis, treatment-resistant schizophrenia (TRS) may involve a different pathophysiology. Neuromelanin (NM), a product of dopamine metabolism in the substantia nigra (SN), indirectly measures long-term dopamine synthesis capacity. Few studies have examined SN NM levels in TRS. Therefore, we investigated the relationship between SN NM levels and treatment responsiveness in schizophrenia. We included age- and sex-matched TRS, patients with schizophrenia in remission of positive symptoms (SZ-R), and healthy controls (HCs). Neuromelanin-sensitive magnetic resonance imaging was used to measure SN NM signals. We also evaluated clinical symptoms and cognitive impairment. We conducted voxel-wise analyses of NM contrast-to-noise ratio (CNR) to compare groups pairwise. Correlation analyses examined relationships between NM signals and symptom severity. Seventy-two participants (n = 24 per group) completed the study. The TRS group had higher dorsal SN CNR than the HC group (510 out of 1948 voxels at p < 0.05, corrected p = 0.005, permutation test). In contrast, no significant differences were observed in the other comparisons. No significant correlations were found between NM CNR and clinical severity. Our findings contrast with previous positron emission tomography studies on dorsal striatal dopamine function. Since the dorsal SN contributes to both the mesolimbic and nigrostriatal pathways, with a relatively greater role in the former, dopamine functions in these pathways may play different roles for treatment responsiveness. Further research with multimodal imaging is needed to examine dopamine function and antipsychotic treatment responsiveness in schizophrenia.Keywords
All Related Versions
This publication has 54 references indexed in Scilit:
- Convergence of Cannabis and Psychosis on the Dopamine SystemJAMA Psychiatry, 2025
- Changes in Incident Schizophrenia Diagnoses Associated With Cannabis Use Disorder After Cannabis LegalizationJAMA Network Open, 2025
- Generalizability and Out-of-Sample Predictive Ability of Associations Between Neuromelanin-Sensitive Magnetic Resonance Imaging and Psychosis in Antipsychotic-Free IndividualsJAMA Psychiatry, 2024
- Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of VarianceBiological Psychiatry, 2020
- Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy StudyBiological Psychiatry, 2019
- Evaluation of Antipsychotic Dose Reduction in Late-Life SchizophreniaJAMA Psychiatry, 2015
- Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in SchizophreniaJAMA Psychiatry, 2015
- Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine FunctionBiological Psychiatry, 2014
- The Nigrostriatal Pathway: Axonal Collateralization and Compartmental Specificity2009
- Striatal Dopamine Synthesis in First-degree Relatives of Patients with SchizophreniaBiological Psychiatry, 2008